Claudia Bartels

University Medical Center Göttingen
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Background Subjective cognitive decline (SCD) is common in older adults and may precede mild cognitive impairment (MCI). Whether longitudinal changes in self- or study partner (SP)-reported SCD improve early identification of individuals at risk for clinical progression, particularly along the Alzheimer’s disease (AD) biological continuum, remains unclear. Methods We pooled data from two longitudinal observational cohorts (DELCODE and ADNI). Cognitively unimpaired (CU) participants were recruited through public advertisement or memory clinics and included if baseline amyloid status, ≥2 SCD assessments, and clinical follow-up were available. SCD was assessed using the Everyday Cognition questionnaire (self- and SP-report). Linear mixed-effects models examined longitudinal associations between SCD trajectories, baseline AD biomarkers, and progression to incident MCI. Multivariable Cox proportional hazards models tested whether one-year changes in SCD predicted subsequent progression. Findings Among 770 participants (median age 69·9years [IQR 66·0–74·6]; 52·6% women; median follow-up 5·0years [4·0-7·0]), amyloid-positive individuals and those who progressed to MCI showed steeper longitudinal increases in both SCD reports. In amyloid-positive participants, only increases in SP-reported SCD differentiated progressors from non-progressors. One-year increases in SP-reported SCD predicted a higher risk of subsequent MCI compared with unchanged scores (hazard ratio 3·24 [95%CI 1·73-6·07]), with effects confined to amyloid-positive participants. Interpretation Longitudinal increases in SP-reported cognitive difficulties, particularly over short intervals, are associated with near-term progression to MCI in amyloid-positive CU older adults. SP-based longitudinal monitoring may represent a low-burden approach to support earlier clinical surveillance in aging populations. Funding German Center for Neurodegenerative Diseases, US National Institutes of Health.

Year:

2026

Background Cognitive decline in Alzheimer's disease (AD) often includes speech impairments, where subtle changes may precede clinical dementia onset. As clinical trials focus on early identification of patients for disease-modifying treatments, digital speech-based assessments for scalable screening have become crucial. Objective This study aimed to validate a remote, speech-based digital cognitive assessment for mild cognitive impairment (MCI) detection through the comparison with gold-standard paper-based neurocognitive assessments. Methods Within the PROSPECT-AD project, speech and clinical data were obtained from the German DELCODE and DESCRIBE cohorts, including 21 healthy controls (HC), 110 participants with subjective cognitive decline (SCD), and 59 with MCI. Spearman rank and partial correlations were computed between speech-based scores and clinical measures. Kruskal-Wallis tests assessed group differences. We trained machine learning models to classify diagnostic groups comparing classification accuracies between gold-standard assessment scores and a speech-based digital cognitive assessment composite score (SB-C). Results Global cognition, as measured by SB-C, significantly differed between diagnostic groups ( H (2) = 30.93, p < 0.001). Speech-based scores were significantly correlated with global anchor scores (MMSE, CDR, PACC5). Speech-based composites for memory, executive function and processing speed were also correlated with respective domain-specific paper-based assessments. In logistic regression classification, the model combining SB-C and neuropsychological tests at baseline achieved a high discriminatory power in differentiating HC/SCD from MCI patients (Area Under the Curve = 0.86). Conclusions Our findings support speech-based cognitive assessments as a promising avenue towards remote MCI screening, with implications for scalable screening in clinical trials and healthcare.

Year:

2025

Objectives: Mild cognitive impairment (MCI) is a heterogeneous clinical syndrome and is important for the diagnosis and management of Alzheimer’s disease (AD). With the expansion of biomarker-based diagnostics, the aim of this study is to clarify the current attitudes towards and the use of MCI, and MCI due to AD, in German memory clinics. Methods: An online survey (50 items) was performed in 2022 among specialized clinicians (N = 45) in German memory clinics to assess the use of MCI and biomarkers in current diagnosis and treatment. Attitudinal and frequency items were assessed with a five-point numeric scale (strongly disagree = 1 to completely agree = 5 and never = 1 to always = 5, respectively). Results: All respondents used MCI as a clinical diagnosis. The benefits of diagnosing MCI were labeling deficits as disease symptoms (M = 4.4, SD = 0.7), improving coping with symptoms (M = 4.1, SD = 0.9), and motivating risk reduction activities (M = 4.0, SD = 0.9). Overall, 37 respondents used specialized diagnostic criteria for MCI due to AD, and all had access to biomarker diagnostics. Patients with MCI due to AD received more frequent counseling on memory training (p < 0.001), other non-pharmacological treatments (p < 0.001), and antidementive drug treatment (p < 0.001) than patients with MCI of other etiologies. Acetylcholinesterase inhibitors were prescribed significantly more frequently to patients with MCI due to AD (p < 0.001) compared to other MCI patients. Conclusions: MCI is commonly used as a clinical diagnosis in German memory clinics. AD biomarker assessment is well established and influences patient counseling and treatment recommendations.

Year:

2025

Zusammenfassung: Für die syndromale Einordnung kognitiver Störungen als Mild Cognitive Impairment (MCI) können unterschiedliche Kriterien genutzt werden. Mit einer Online-Umfrage unter Zentren des Deutschen Netzwerks Gedächtnisambulanzen e. V. (DNG) wurde die Zielsetzung verfolgt, den Status quo zum Umgang mit operationalisierten Kriterien in Gedächtnisambulanzen zu ermitteln. Dabei gaben neuropsychologisch Tätige an, relevante kognitive Domänen sowie zusätzlich subjektive Angaben (häufig bis immer 72.1 %) und weitere Befunde in der Gesamtinterpretation zu berücksichtigen (Fremdanamnese häufig bis immer 81.4 %, weitere Untersuchungsbefunde 69.8 %). Überwiegend erfolgt eine Differenzierung verschiedener MCI-Formen (amnestisch vs. nonamnestisch MCI bei 83.7 %, single vs. multidomain bei 72.1 %). In 67.4 % der Einrichtungen werden explizit einheitliche Kriterien angewendet, mehrheitlich von Molinuevo et al. (2017 ; 23.3 %). Fast alle Befundende (93 %) fühlen sich bei der Diagnosevergabe sicher. Die Umfrageergebnisse spiegeln zentrumsintern, nicht jedoch zentrumsübergreifend, eine weitgehende Standardisierung wider und bieten eine Ausgangsbasis für das Fernziel einer Harmonisierung.

Year:

2025

Zusammenfassung Seit seiner Einführung im Jahr 1999 hat sich der Begriff des Mild Cognitive Impairment (MCI) als klinisches Syndrom in der wissenschaftlichen und klinischen Praxis etabliert. Technische und wissenschaftliche Fortschritte machten eine regelmäßige Aktualisierung von Forschungskriterien erforderlich. In der Entwicklung kam es so zu einer stärker biologischen Definition und dem Einbezug von Biomarker-basierten Kriterien, während die klinischen Kernkriterien im Wesentlichen unverändert blieben. Das klinische MCI-Kernkriterium zu objektivierbaren kognitiven Defiziten erlaubt eine konkrete Operationalisierung und hat wiederum zur Entwicklung verschiedener neuropsychologisch-operationalisierter Kriterien geführt. Weitere Ansätze, die sensitiver für erste kognitive Veränderungen sein könnten oder auch stärker das Kriterium des kognitiven Abbaus berücksichtigen, könnten künftig ebenfalls dafür genutzt werden. Dabei müssen für die Anwendung neuropsychologisch-operationalisierter Kriterien bestimmte Voraussetzungen erfüllt sein, wie die Erfassung relevanter kognitiver Domänen mit angemessen normierten Testverfahren in einem ausreichenden Umfang. Eine standardisierte und konsistente Nutzung dieser Kriterien könnte die hohe Variation in MCI-Prävalenzraten reduzieren sowie prognostische Einschätzungen und Behandlungsentscheidungen in der klinischen Routine angleichen. Erhebungen zum Ist-Zustand in deutschen Gedächtnisambulanzen zeigen, dass perspektivisch die Möglichkeit einer einrichtungsübergreifenden Verständigung auf ein Kriterienset i.S. einer Harmonisierung möglich wäre. Dennoch bliebe bei einer Festlegung auf eine Operationalisierung weiterhin abschließend das klinische Urteil mit angemessener Würdigung individueller Einflussfaktoren ausschlaggebend für eine MCI-Diagnose. Die vorliegende Arbeit liefert einen Überblick und Einordnung zu klinischen und neuropsychologisch-operationalisierten Kriterien, deren Herausforderungen und neuen Entwicklungen, um erste kognitive Veränderungen frühzeitig und adäquat zu detektieren.

Year:

2025

Affiliations: In the published publication [...]

Year:

2024

Collaborators (11)

Matthias Schmid

Full professor / Director

University of Bonn

GERMANY
View details

Ayda Rostamzadeh

University of Cologne

GERMANY
View details

Josef Priller

-

UNITED KINGDOM
View details

Matthis Synofzik

Professor

Hertie Institute for clinical brain research

GERMANY
View details

Robert Perneczky

Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Emrah Düzel

Deutsches Zentrum für Neurodegenerative Erkrankungen

GERMANY
View details

Nicklas Linz

Deutsches Forschungszentrum für Künstliche Intelligenz GmbH

GERMANY
View details

Sophia Stoecklein

LMU University Hospital

GERMANY
View details

Lutz Froelich

Head

Zentralinstitut für Seelische Gesundheit

GERMANY
View details

Björn H. Falkenburger

Academic Staff

Technische Universität Dresden

GERMANY
View details

Stefan Teipel

Rostock University Medical Center

GERMANY
View details